Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 614

1.

Belimumab: review of use in systemic lupus erythematosus.

Boyce EG, Fusco BE.

Clin Ther. 2012 May;34(5):1006-22. doi: 10.1016/j.clinthera.2012.02.028. Epub 2012 Mar 30. Review.

PMID:
22464040
2.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA; BLISS-52 Study Group.

Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.

PMID:
21296403
3.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group.

Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613.

4.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.

5.

Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.

Wiglesworth AK, Ennis KM, Kockler DR.

Ann Pharmacother. 2010 Dec;44(12):1955-61. doi: 10.1345/aph.1P360. Epub 2010 Nov 16. Review.

PMID:
21081710
6.

Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.

Borba HH, Wiens A, de Souza TT, Correr CJ, Pontarolo R.

BioDrugs. 2014 Apr;28(2):211-28. doi: 10.1007/s40259-013-0074-x. Review.

PMID:
24190520
7.

Belimumab and the clinical data.

Shum K, Askanase A.

Curr Rheumatol Rep. 2012 Aug;14(4):310-7. doi: 10.1007/s11926-012-0264-4.

PMID:
22614721
8.

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W.

Ann Rheum Dis. 2012 Aug;71(8):1343-9. doi: 10.1136/annrheumdis-2011-200937. Epub 2012 Feb 15.

9.

Belimumab for the management of systemic lupus erythematosus.

Lutalo PM, D'Cruz DP.

Expert Opin Biol Ther. 2012 Jul;12(7):957-63. doi: 10.1517/14712598.2012.682980. Epub 2012 May 30. Review.

PMID:
22646798
11.

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.

Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group.

J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1.

12.

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.

Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA; BLISS-52 and BLISS-76 Study Groups.

Ann Rheum Dis. 2012 Nov;71(11):1833-8. doi: 10.1136/annrheumdis-2011-200831. Epub 2012 May 1.

13.

Novel evidence-based systemic lupus erythematosus responder index.

Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1143-51. doi: 10.1002/art.24698.

14.

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups.

Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995.

15.

Belimumab: in systemic lupus erythematosus.

Burness CB, McCormack PL.

Drugs. 2011 Dec 24;71(18):2435-44. doi: 10.2165/11208440-000000000-00000. Review.

PMID:
22141386
16.
17.

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).

Kalunian KC, Merrill JT, Maciuca R, McBride JM, Townsend MJ, Wei X, Davis JC Jr, Kennedy WP.

Ann Rheum Dis. 2016 Jan;75(1):196-202. doi: 10.1136/annrheumdis-2014-206090. Epub 2015 Jun 2.

PMID:
26038091
18.

Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.

Dennis GJ.

Clin Pharmacol Ther. 2012 Jan;91(1):143-9. doi: 10.1038/clpt.2011.290. Epub 2011 Nov 30. Review.

PMID:
22130121
19.

Re-evaluation of biologic therapies in systemic lupus erythematosus.

Bruce IN.

Curr Opin Rheumatol. 2010 May;22(3):273-7. doi: 10.1097/BOR.0b013e3283374e78. Review.

PMID:
20177385
20.

Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.

Jordan NP, D'Cruz DP.

Expert Opin Drug Metab Toxicol. 2015;11(10):1635-45. doi: 10.1517/17425255.2015.1077808. Epub 2015 Sep 1. Review.

PMID:
26327145

Supplemental Content

Support Center